1) Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA.
Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies.Top Magn Reson Imaging. 2008
2) Camastra GS, Cacciotti L, Marconi F, Sbarbati S, Pironi B, Ansalone G.
Late enhancement detected by cardiac magnetic resonance imaging in acute myocarditis mimicking acute myocardial infarction: location patterns and lack of correlation with systolic function. J Cardiovasc Med 2007.
3) Krombach GA, Hahnen C, Lodemann KP, Krämer N, Schoth F, Neizel M, Boeringer J, Günther RW, Kelm M, Kühl H.
Gd-BOPTA for assessment of myocardial viability on MRI: changes of T1 value and their impact on delayed enhancement. Eur Radiol 2009.
4) Tumkosit M, Puntawangkoon C, Morgan TM, Clark HP, Hamilton CA, Ntim WO, Clark PB, Hundley WG.
Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. J Comput Assist Tomogr 2009.
5) Schlosser T, Hunold P, Herborn CU, Lehmkuhl H, Lind A, Massing S, Barkhausen J.
Myocardial infarct: depiction with contrast-enhanced MR imaging-comparison of gadopentetate and gadobenate. Radiology 2005.
6) Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A.
Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol 2006.
7) Bauner KU, Reiser MF, Huber AM.
Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol 2009.